MedTrace Logo

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05288855 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-02-10

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).

Conditions

  • Adolescent Lupus Nephritis
  • Pediatric Lupus Nephritis

Interventions

DRUG

Voclosporin

calcineurin inhibitor

DRUG

Placebo Oral Capsule

matching placebo capsule

Sponsors & Collaborators

  • Aurinia Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-10
Primary Completion
2025-07-03
Completion
2025-07-03
FDA Drug
Yes

Countries

  • United States
  • Colombia
  • Japan
  • Mexico
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05288855 on ClinicalTrials.gov